All In Biotech

Drug Trial Radar · NCT04573803

Pharmacological Management of Seizures Post Traumatic Brain Injury

Pharmacological Management of Seizures Post Traumatic Brain Injury (MAST)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,649 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,649

Planned (sponsor's estimate)

Start

Mar 1, 2021

Primary completion

Mar 1, 2026

Study completion Mar 1, 2028

Sponsor

Lead sponsor
Cambridge University Hospitals NHS Foundation TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Cambridge
First posted
Oct 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall aim of the MAST trial is to define best practice in the use of anti-epileptic drugs (AEDs) for patients following a traumatic brain injury (TBI). The trial will consist of two parts. The first part aims to answer whether a shorter or a longer course of AEDs is better to prevent further seizures in patients who have started having seizures following TBI (MAST - duration). The second part aims to answer whether a 7-day course of either Phenytoin or Levetiracetam should be used for patients with a serious TBI to prevent seizures from starting (MAST- prophylaxis).

Conditions

  • Traumatic Brain Injury
  • Post Traumatic Seizures

Interventions

  • Phenytoin SodiumDrug

    Dosing will be as prescribed clinically by the treating physician. Phenytoin Sodium may be administered orally, intravenously or via nasogastric tube.

  • LevetiracetamDrug

    Dosing will be as prescribed clinically by the treating physician.Levetiracetam may be administered orally, intravenously or via nasogastric tube.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MAST-DURATION: Occurrence of late PTSTime frame: Within 24 months post traumatic brain injury
  2. MAST-PROPHYLAXIS: Occurrence of PTSTime frame: Within 2 weeks post TBI

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.